Sale!

Letrozole Tablets 2.5mg (Letrozole “F”® / レトロゾール錠2.5mg「F」)

元の価格は JPY ¥5,850 でした。現在の価格は JPY ¥4,797 です。

Japanese Aromatase Inhibitor (Letrozole 2.5mg). Oral tablet for postmenopausal breast cancer, controlled ovarian stimulation, and ovulation induction. 30 tablets [10 tablets (PTP) x 3]. Mfd. by Fuji Pharma Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥5,382
10 - 19 12% JPY ¥5,148
20 + 18% JPY ¥4,797
SKU: LET-25-TAB Category:

Description

Product Overview / 商品概要

Letrozole Tablets 2.5mg “F” (レトロゾール錠2.5mg「F」)
Generic: Letrozole / レトロゾール
Therapeutic Category: Aromatase Inhibitor / アロマターゼ阻害剤
Manufactured by: Fuji Pharma Co., Ltd. / 富士製薬工業株式会社

Composition & Specification / 組成・規格

Active Ingredient: Letrozole 2.5mg per tablet / 1錠中 レトロゾール 2.5mg
Additives: Lactose, Corn starch, Cellulose, Anhydrous silicic acid, Sodium starch glycolate, Magnesium stearate, Hypromellose, Macrogol, Talc, Titanium oxide, Iron sesquioxide / 乳糖、トウモロコシデンプン、セルロース、無水ケイ酸、デンプングリコール酸ナトリウム、ステアリン酸マグネシウム、ヒプロメロース、マクロゴール、タルク、酸化チタン、三二酸化鉄
Appearance: Reddish-yellow film-coated tablet, diameter 6.2mm, thickness 3.2mm, weight 100mg, identification code FJ65
外観: 帯赤黄色のフィルムコーティング錠、直径6.2mm、厚さ3.2mm、質量100mg、識別コード FJ65

Indications / 効能効果

EN: Postmenopausal breast cancer / Controlled ovarian stimulation in assisted reproductive technology / Ovulation induction in polycystic ovary syndrome / Ovulation induction in unexplained infertility
JA: 閉経後乳癌/生殖補助医療における調節卵巣刺激/多嚢胞性卵巣症候群における排卵誘発/原因不明不妊における排卵誘発

Dosage and Administration / 用法用量

EN: The usual adult dose is 2.5mg of letrozole orally once daily. The usual dose is 2.5mg of letrozole orally once daily for 5 days starting from day 3 of the menstrual cycle. If sufficient effect is not achieved, the dose may be increased to 5mg once daily from the next cycle onward.
JA: 〈閉経後乳癌〉通常、成人にはレトロゾールとして1日1回2.5mgを経口投与する。〈生殖補助医療における調節卵巣刺激、多嚢胞性卵巣症候群における排卵誘発、原因不明不妊における排卵誘発〉通常、レトロゾールとして1日1回2.5mgを月経周期3日目から5日間経口投与する。十分な効果が得られない場合は、次周期以降の1回投与量を5mgに増量できる。

Contraindications / 禁忌

EN: Pregnant women or women who may be pregnant / Breastfeeding women / Patients with a history of hypersensitivity to any component of this product / Patients with active thromboembolic disease (for ART/ovulation induction indications)
JA: 妊婦又は妊娠している可能性のある女性/授乳婦/本剤の成分に対し過敏症の既往歴のある患者/活動性の血栓塞栓性疾患の患者(生殖補助医療・排卵誘発適応時)

Regulatory Information / 規制情報

Approval No.: 22700AMX00544
Sales Started: June 2015 / 2015年6月
Classification Code: 874291, 872529
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 30 tablets [10 tablets (PTP) x 3] / 30錠[10錠(PTP)×3]
Other Available Packages (by special order): 30 tablets [10 tablets (PTP) x 3] / 100 tablets [10 tablets (PTP) x 10]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Letrozole Tablets 2.5mg (Letrozole “F”® / レトロゾール錠2.5mg「F」)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Letrozole Tablets 2.5mg (Letrozole "F"®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.